Search Results
Oct 20, 2025, 07:30 ET Endo Launches First and Only Generic Version of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in the United States
Abnormal body odor, including from skin, hair, and urine Retching and gagging Dysgeusia or burning sensation in mouth
More news about: Endo USA, Inc.
Oct 20, 2025, 06:55 ET Protocatechuic Acid Market worth $24.0 million by 2030 - Exclusive Report by MarketsandMarkets™
diabetes, and cardiovascular diseases has further accelerated PCA's use in drug formulations and dietary supplements. At the same time, its antioxidant and skin-protective capabilities are increasingly utilized in the booming personal care and cosmetics sector. Moreover, technological advancements in biotechnology
More news about: MarketsandMarkets
Oct 20, 2025, 06:00 ET IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
look forward to advancing this combination in the ongoing registrational OptimUM-02 trial," said Meredith McKean, M.D., MPH, Director of Melanoma and Skin Cancer Research for Sarah Cannon Research Institute and principal investigator on the trial. Metastatic uveal melanoma is a rare
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 02:37 ET Immunotherapy After Surgery Shows Promise in Treating Rare, Aggressive Skin Cancer
physician. Merkel cell carcinoma, also called neuroendocrine carcinoma of the skin, is rare, occurring in no more than 3 in 1 million people, most often in people over age 50 and as a bump on the skin. The cancer is known to spread fast and aggressively, with fewer than half of those with the
More news about: NYU Langone Health System
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
ethanol-free) emollient cream is recommended for dry skin. When initiating treatment, administer alcohol-free emollient cream to reduce the risk of dermatologic adverse reactions. Consider prophylactic measures (eg, use of oral antibiotics). If skin reactions develop, start topical corticosteroids
More news about: Johnson & Johnson
Oct 19, 2025, 04:59 ET Proya Cosmetics präsentiert auf der Cosmetic 360 seine Vision für die Zukunft der Schönheit und stellt wissenschaftliche Fortschritte und Markeninnovationen vor
ultrafeinem Puder für ein leichtes Finish und eine untere Schicht mit Concealer für eine präzise Korrektur. Die Formel enthält den bahnbrechenden Magnetic Skin-Adhering Powder für einen nahtlosen, porzellanähnlichen Schimmer und einen patentierten Hyaluronsäure-verkapselten Puder, der trockene Stellen
More news about: Proya Cosmetics
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate compared to PADCEV as a single agent. The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash. Grade 3-4 skin reactions occurred in 17%
More news about: Astellas Pharma Inc.
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias" and "[t]o that end,
More news about: Pomerantz LLP
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
your healthcare provider right away if you get symptoms of gallbladder problems, which may include: pain in your upper stomach (abdomen), yellowing of skin or eyes (jaundice), fever, and clay-colored stools food or liquid getting into the lungs during surgery
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
your healthcare provider right away if you get symptoms of gallbladder problems, which may include: pain in your upper stomach (abdomen), yellowing of skin or eyes (jaundice), fever, and clay-colored stools food or liquid getting into the lungs during surgery or other procedures that use anesthesia
More news about: Novo Nordisk
Oct 17, 2025, 10:15 ET Connected Worker Market worth $20.18 billion by 2030 - Exclusive Report by MarketsandMarkets™
such as TotalEnergies and Mitsubishi Chemicals. Rugged wristbands and Bluetooth bracelets from Lansitec monitor vital signs, including heart rate and skin temperature, and provide SOS alert functions, which are vital for worker safety in hazardous industrial sites.
More news about: MarketsandMarkets
Oct 17, 2025, 10:00 ET 4 Student Teams' Innovations Win 2025 Collegiate Inventors Competition
infant jaundice in limited-resource settings. BiliRoo is a wearable infant sling that combines filtered sunlight phototherapy and "kangaroo care" (skin-to-skin contact) to enable parental involvement and potential at-home use. GRADUATE:
More news about: Collegiate Inventors Competition
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
inhibitor-based ADCs, with manageable hematologic toxicities as the most common treatment-related adverse events. Only low-grade and infrequent mucosal and skin toxicities were observed, demonstrating a favorable tolerability profile. "We are excited by the impressive and durable efficacy
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
yellowing of your skin or the white part of your eyes (jaundice) dark or brown (tea colored) urine pain on the
More news about: Boehringer Ingelheim
Oct 17, 2025, 09:03 ET SEATTLE REIGN FC ANNOUNCES MULTI-YEAR UPPER-BACK KIT PARTNERSHIP WITH PAULA'S CHOICE SKINCARE
over 30 years, we've broken down the science of skincare, busted beauty myths and made products with ingredients that research proves can transform skin. Established in 1995 by beauty expert Paula Begoun, Paula's Choice is deeply rooted in our founder's commitment to customer advocacy and education. Our
More news about: Paula's Choice
Oct 17, 2025, 09:00 ET Curology Introduces DayPrimeRx- The first-ever prescription acne treatment and primer
Dermatologist and Medical Director at Curology. "DayPrimeRx eliminates that choice, giving patients one product that immediately blurs the skin, treats skin with prescription actives over time, and holds makeup in place for up to 12 hours thereby maximizing results and minimizing effort."
More news about: Curology
Oct 17, 2025, 08:34 ET Harnessing Molecular Medicine to Accelerate Wound Healing
The Pressure Relief & Prevention Series is specifically designed to address skin injuries caused by medical devices or prolonged immobility. Common scenarios include facial pressure from BiPAP masks, skin damage from drainage tubes or nasogastric tubes, and localized pressure injuries in bedridden
More news about: TAICEND TECHNOLOGY CO,. LTD.
Oct 17, 2025, 08:30 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or "HS").
More news about: Hagens Berman Sobol Shapiro LLP
Oct 17, 2025, 08:30 ET Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA
More news about: Neurocrine Biosciences, Inc.
Oct 17, 2025, 07:31 ET Truekind® to Launch TrueCool Wireless Menopause Bra and TrueCool Mid-Waist Menopause Brief
and all its hormonal fluctuations. I wanted to create a collection that helps other women like myself who are experiencing the hot flashes, irritated skin, and sore, swollen, and tender breasts that are constantly fluctuating in size," she shared. "Truekind is a solutions-based brand that truly cares about
More news about: Truekind
Oct 17, 2025, 07:00 ET CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
ReactionsTreatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.
More news about: Insmed Incorporated
Oct 17, 2025, 06:12 ET Weekly Recap: 13 Consumer Press Releases You Need to See
year-long partnership will extend into community events and opportunities to unlock complimentary access, creating inclusive spaces for the care of both skin and soul.
More news about: PR Newswire
Oct 17, 2025, 05:49 ET Adhesion Barrier Market 2025-30 Outlook Shows 7.5% CAGR as North America Leads Global Growth, Says Mordor Intelligence
Active Wound Care Market : The Active Wound Care Market Report is Segmented by Product (Biomaterials, Skin Substitutes, Growth Factors), End User (Hospitals, Specialty Wound Clinics, Home Healthcare), Application (Chronic Wounds, Acute Wounds), and Geography
More news about: Mordor Intelligence Private Limited
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
populations.[1] HS, which affects approximately 1%-4% of people in the U.S., is a chronic, inflammatory, recurrent skin condition characterized by painful nodules, abscesses, comedones, fistulas, sinus tracts, and scarring in intertriginous areas. Adolescent HS shares
More news about: Celltrion USA
Oct 16, 2025, 17:36 ET Berger Montague PC Investigating Claims on Behalf of MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors After Class Action Filing
executives made false and misleading statements regarding the Company's only drug candidate, sonelokimab (SLK), in testing as a treatment for certain skin conditions. The complaint alleges that the Company repeatedly promoted SLK's Nanobody structure as providing superior clinical advantages
More news about: Berger Montague